VBI Vaccines Current Financial Leverage
| VBIV Stock | USD 0.59 0.02 3.28% |
VBI Vaccines holds a debt-to-equity ratio of 0.315. At this time, VBI Vaccines' Long Term Debt To Capitalization is fairly stable compared to the past year. Total Debt To Capitalization is likely to climb to 0.92 in 2024, despite the fact that Net Debt To EBITDA is likely to grow to (0.52). VBI Vaccines' financial risk is the risk to VBI Vaccines stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
VBI Vaccines' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. VBI Vaccines' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps VBI Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect VBI Vaccines' stakeholders.
For most companies, including VBI Vaccines, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running VBI Vaccines the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 0.8206 | Book Value 0.315 | Operating Margin (14.49) | Return On Assets (0.29) | Return On Equity (2.59) |
VBI |
VBI Vaccines Financial Leverage Rating
VBI Vaccines bond ratings play a critical role in determining how much VBI Vaccines have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for VBI Vaccines' borrowing costs.| Piotroski F Score | 2 Frail |
| Beneish M Score | -2.21 Possible Manipulator |
VBI Vaccines Debt to Cash Allocation
As VBI Vaccines follows its natural business cycle, the capital allocation decisions will not magically go away. VBI Vaccines' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 53.04 M in liabilities with Debt to Equity (D/E) ratio of 0.32, which is about average as compared to similar companies. VBI Vaccines has a current ratio of 2.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist VBI Vaccines until it has trouble settling it off, either with new capital or with free cash flow. So, VBI Vaccines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VBI Vaccines sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VBI to invest in growth at high rates of return. When we think about VBI Vaccines' use of debt, we should always consider it together with cash and equity.VBI Vaccines Total Assets Over Time
VBI Vaccines Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the VBI Vaccines' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of VBI Vaccines, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a VBI Vaccines debt ratio should be compared their industry average or other competing firms.VBI Net Debt
Net Debt |
|
Understaning VBI Vaccines Use of Financial Leverage
VBI Vaccines financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures VBI Vaccines's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of VBI Vaccines assets, the company is considered highly leveraged. Understanding the composition and structure of overall VBI Vaccines debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to VBI Vaccines' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of VBI Vaccines' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | 29.4 M | 30.8 M | |
| Short and Long Term Debt Total | 53 M | 55.7 M | |
| Short Term Debt | 51.7 M | 54.3 M | |
| Long Term Debt | 56.2 M | 59 M | |
| Short and Long Term Debt | 58.4 M | 61.3 M | |
| Long Term Debt Total | 56.2 M | 59 M | |
| Net Debt To EBITDA | (0.55) | (0.52) | |
| Debt To Equity | 7.05 | 7.40 | |
| Interest Debt Per Share | 3.92 | 6.74 | |
| Debt To Assets | 0.61 | 0.64 | |
| Long Term Debt To Capitalization | 0.15 | 0.21 | |
| Total Debt To Capitalization | 0.88 | 0.92 | |
| Debt Equity Ratio | 7.05 | 7.40 | |
| Debt Ratio | 0.61 | 0.64 | |
| Cash Flow To Debt Ratio | (1.15) | (1.21) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:Check out the analysis of VBI Vaccines Fundamentals Over Time. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.